U.S. Markets open in 5 hrs 51 mins

Navidea Biopharmaceuticals, Inc (NAVB)

NYSE MKT - Nasdaq Real Time Price. Currency in USD
Add to watchlist
0.46+0.00 (+0.59%)
At close: 3:59PM EDT
People also watch
IMUCCLSNGALEMSTXTHLD
  • Msg 19846 of 19874 at 7/24/2017 11:41:14 AM by FIRAC

    The following message was updated on 7/24/2017 11:43:13 AM.

    patent protection expanded

    Recent 371 publication date July 20, 2017 expands the 2015 patent COMPOUNDS AND COMPOSITIONS FOR TARGETING MACROPHAGES AND OTHER MANNOSE-BINDING C-TYPE LECTIN RECEPTOR HIGH EXPRESSING CELLS AND METHODS OF TREATING AND DIAGNOSIS USING SAME

    An impressive list of claims for diagnosing and treating sarcoma, lymphoma, leukemia, carcinoma, blastoma, melanoma, or germ cell tumor; Kaposi's sarcoma; rheumatoid arthritis; autoimmune disease, an inflammatory disease; AIDS, HIV infection and Leishmaniasis
    and others.

    There are various sites to view patents online. I find the link below is easier to view than the government USPTO website. http://www.freepatentsonline.com/y2017/0202969.html

    COMPOUNDS AND COMPOSITIONS FOR TARGETING MACROPHAGES AND OTHER MANNOSE-BINDING C-TYPE LECTIN RECEPTOR HIGH EXPRESSING CELLS AND METHODS OF TREATING AND DIAGNOSIS USING SAME - OHIO STATE INNOVATION FOUNDATION
    Provided are compounds and compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells and methods of treatment and diagnosis using such compounds and
    www.freepatentsonline.com
  • In honor of our dearly departed Joseph, I will let you guys know that we are up 4% today! We need something great to happen today.
  • This is going stale.
  • who knows when second quarter earnings are coming out

    second , based on the January 2018 one dollar call they are not expecting much to happen between now and then. you can buy them for five cents
  • joseph
    Duke of Westchester
    please make sure the door does not hit you on the way out
  • For those who say RS never work. XRX did a RS split 6/14/17 and the SP was $27.48 and now its $30.56 (up 11.2%) Naturally most companies see their SP go down after a RS but thats largely because the companies are in trouble in the first place. 7/5/17 NAVB voted down the RS and since then, the SP is down 6.2%. The question is "would NAVB be trading even lower if the RS was approved?"
  • I bought in on 8/14/012. @ 3.58 (Neoprobe).. regrettably with some of my kids savings thinking it was promising. That is down 84% Now Goldberg wants to blame shareholders for not approving the dumbest idea ever . Please. Get off your bum and promote this where you still have the rights. Good job ...down 84%..
  • Courtesy of moneyonomics-IV,otl...

    Msg 16093 of 16093 at 7/26/2017 3:38:51 PM by

    moneyonomics

    report abuse
    The following message was updated on 7/26/2017 3:39:58 PM.

    NAVB details its 4 active and its completed grant programs

    https://www.investorvillage.com/groups.asp?mb=16085&mn=16093&pt=msg&mid=17385959

    http://www.navidea.com/technology/grant-funding

    Grant Funding :: Navidea Biopharmaceuticals, Inc. (NAVB)
    www.navidea.com
  • My wife and her cousin went to the Dodger game tonight and what a game it was. Besides the Dodgers m aking a comeback win, My wife and her clousin put %10 into the 50/50 pool that was worth $44.500 and they won it. They won the $22.250 pool. After taxes they will get around $17,000 to split. Turned out to be a good day after all.
  • how is it , that we were down two cents in pre market , and now we are up
  • Another day, another disappointment. Please buy out at 5.30 a share and take this Navb private. Pls
  • KTOV = Mcap $16 Mil /Cash $17 Mil / ULTRA Low float / NDA submission for potential Blockbuster this Quarter = 20 BAGGER ..ONE OF THE BIGGEST BIOTECH OPPORTUNITY EVER ! Thank me later guys

    Kitov Pharma (KTOV)

    Market Cap: $17 M
    Cash $17 M
    Price: $1.50

    Shares Out: 10.6 Million

    Kitov Pharmaceuticals Initiates NDA Filing for KIT-302 as a Treatment for Osteoarthritis and Hypertension
    https://baystreet.ca/articles/research_reports/lifesci/Kitov062717.pdf

    Kitov Expects to Submit an NDA for KIT-302 in the Third Quarter 2017.Kitov announced that it began the process of compiling the documents necessary to file an NDA for its lead asset KIT-302 as a treatment for patients who experience both osteoarthritis and hypertension. The Company hired Parexel International Corporation, a clinical research organization, to digitalize and formally submit its NDA application. Kitov expects the filing to occur during the third quarter of 2017, with a potential FDA approval during the second quarter of 2018.

    KIT-302 is a combination drug that treats osteoarthritis pain and hypertension simultaneously

    Primary efficacy endpoint achieved Lead drug candidate KIT-302 achieved its primary efficacy endpoint in a pivotal Phase III trial

    Marketing potential Pipeline candidates address large, multi-billion dollar markets

    Products

    Kitov’s current pipeline products, KIT-301 and KIT-302, are combination drugs that treat OA pain and HTN simultaneously. In December 2015, KIT-302 successfully achieved the primary efficacy endpoint for its Phase III clinical trial. In August 2016, the United States Patent Office issued a patent covering KIT-302.

    Market

    Of the 27 million Americans with OA, 50% also suffer from HTN, which is also a common side effect of stand-alone OA drugs. With no single medication currently treating both conditions, KIT-301 and KIT-302 are targeting this multi-billion dollar market.

  • I can't believe it! We went up! Yaaaaa.
    Wait... Not so fast. Down more in after hours. This is at a time that other stocks at record highs!! If this isn't a dismal failure stock, tell me what is. Enron clone? Navb?
  • Need management to make some positive decisions. I would have supported a reverse split of 10 to 1. That would make it close to a $5 stock. Then they could split the company. Come on management start earning your pay.
  • Sayre Therapeutics article ET Healthworld by CEO Shukrit Shimote dated Jly 15, 2017 wrote about areemement for the exclusive license and NAVB for development and commercialization of Tc 99m Tillmanocept in India. Mr Chimote 10 million cases in INDIA and expected to may come close to 20,000,000 cases by 2025.. very interesting. check out these many articles HEALTHWORD NEWS FROM ECONOMIC TIMES!!!
  • Now another PR disaster ===getting robbed by a PI firm while investigating each other. Never a reverse split. I want all my shares to go up a buck not 1/20th of them. So they get a reverse split and then the officers, MG and the board get the same number of scoops full of free shares and sell them at $5??? Never--- if they ever reverse split they should always be required to sell their shares at 1/20th of their worth!!! that should get these freeloaders hustling. And lets say they are promised 20K shares at a milestone in the future and the reverse split has those share then worth $5 at that time. No way!!! Their milestone number of gift shares promised is reduced 1/20th as soon as they get a RS or they get 1/20th of the PPS. We can get robbed by CRG, PI firms but the Directors and Officers want to make themselves immune as they concoct more ways to rob us while the sales languish. They are churning us. We need to have a compensation committee that isn't inbred. FYI-- with NAVB since 2000.
  • Another article quoting MG?
    "Navidea CEO: Splitting company could boost struggling stock". Remember when MG stated when he took over that they'd communicate more frequently w shareholders? Now he seems afraid to and only speaks through his local newspaper. Get on the phone and answer shareholder questions MG!
  • [!] Freshly upgraded to now display all possible spread combinations - Option spread traders have a look at CreditSpreads.io, cost free live list of mathematically gainful option credit spreads for the upcoming four weeks, sometimes including spreads for NAVB! High probability option credit spreads offer a way to invest with determined risk and the max profit gained up front. CreditSpreads.io targets solely the option spreads which meet its stringent standards for probability and profit, and ensures sustained profitability by telling you of any upcoming events which can affect the trade. http://creditspreads.io

    CreditSpreads.io
    Sustainable, high probability, defined risk stock option trading opportunities.
    creditspreads.io
  • This Goldberg better watch himself and what he says. He's acting childish and greddy.
  • perfect example of a robed reversed split is ARNA ARENA PEAKED AND NOW HEADING BAK DOWN